Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
776 people get ITMN articles and Market Currents by email alert.
Get email alerts on ITMN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 17, 2013)
-
-
PR Newswire (Feb 21, 2013)
-
4 Biotech Stocks On The ClockStock Traders Daily • Tue, Feb 19 -
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 11, 2013)
-
-
-
PR Newswire (Jan 14, 2013)
-
PR Newswire (Jan 2, 2013)
-
InterMune Gearing Up For Another Round With The FDABrian L. Wilson • Thu, Nov 29, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
InterMune Gearing Up For Another Round With The FDABrian L. Wilson • Thu, Nov 29, 2012
-
-
-
-
InterMune: European Market May Open Its Doors to This BiotechIan Wyatt • Fri, Jan 14, 2011 -
Hedge Fund Balyasny Ramps Up Intermune PositionMarket Folly • Tue, Jun 29, 2010 -
-
Intermune Drops Right Back Down AgainDerek Lowe • Wed, May 5, 2010 -
InterMune's Surprising RiseDerek Lowe • Thu, Mar 11, 2010
-
-
-
4 Biotech Stocks On The ClockStock Traders Daily • Tue, Feb 19
-
-
-
-
-
-
-
-
7 Liquid Small-Cap Healthcare Stocks Rated Buy Or Better By AnalystsZetaKap • Tue, Aug 28, 2012 -
-
6 Biotech Stocks That Analysts Give The Green LightZetaKap • Fri, Jul 27, 2012
-
-
-
-
-
-
-
-
InterMune's CEO Discusses Q3 2012 Results - Earnings Call TranscriptWed, Nov 7, 2012
-
InterMune's CEO Discusses Q2 2012 Earnings - Earnings Call TranscriptMon, Jul 23, 2012
-
InterMune, Inc. Q3 2009 Earnings Call TranscriptTue, Nov 10, 2009
-
InterMune, Inc. Q2 2009 Earnings Call TranscriptThu, Aug 6, 2009
-
InterMune, Inc. Q1 2009 Earnings Call TranscriptThu, Apr 30, 2009
-
InterMune, Inc., Q4 2008 Earnings Call TranscriptThu, Feb 26, 2009
-
InterMune, Inc. Q3 2008 Earnings Call TranscriptWed, Nov 19, 2008
-
InterMune Inc. Q1 2008 Earnings Call TranscriptMon, May 19, 2008
-
InterMune Inc. Q4 2007 Earnings Call TranscriptSun, Feb 10, 2008
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Feb 21, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 11, 2013)
-
PR Newswire (Jan 14, 2013)
-
PR Newswire (Jan 2, 2013)
-
at MarketWatch.com (Nov 8, 2012)
-
PR Newswire (Nov 7, 2012)
-
PR Newswire (Oct 31, 2012)
-
at MarketWatch.com (Oct 3, 2012)
-
at CNBC.com (Oct 3, 2012)
-
PR Newswire (Oct 2, 2012)
-
PR Newswire (Sep 11, 2012)
-
PR Newswire (Sep 3, 2012)
-
PR Newswire (Aug 27, 2012)
-
at Fox Business (Aug 20, 2012)
ITMN vs. ETF Alternatives
Company Description
We are a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. Hepatology is the field of medicine concerned with the diagnosis and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, April 24, 4:12 PM InterMune (ITMN): Q1 EPS of -$0.64 beats by $0.09. Revenue of $10.5M misses by $0.03M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 24, 12:10 AM Notable earnings after Wednesday’s close: AFL, AIZ, AKAM, ANGI, ARII, ARRS, ASGN, AVG, BAS, BDN, CAKE, CCI, CDNS, CLF, CLGX, CMO, CMRE, COG, CROX, CTXS, DRE, DRWI, EFX, EQIX, FFIV, FIO, FLS, GGG, INFN, ISIL, ITMN, JAH, KEX, LOGI, LPS, LRCX, LSI, MLNX, NEU, NOW, OIS, ORLY, OTEX, PDH, PMTC, QCOM, RJF, RYL, SCI, SKX, SRCL, SUSQ, SYK, TAL, TER, TEX, TQNT, TSCO, TWI, VAR, WCN, WDC, WLL, XLNX, XNPT, ZNGA 1 Comment [Earnings]
- Tuesday, April 23, 5:35 PM Notable earnings after Wednesday’s close: AFL, AIZ, AKAM, ANGI, ARII, ARRS, ASGN, AVG, BAS, BDN, CAKE, CCI, CDNS, CLF, CLGX, CMO, CMRE, COG, CROX, CTXS, DRE, DRWI, EFX, EQIX, FFIV, FIO, FLS, GGG, INFN, ISIL, ITMN, JAH, KEX, LOGI, LPS, LRCX, LSI, MLNX, NEU, NOW, OIS, ORLY, OTEX, PDH, PMTC, QCOM, RJF, RYL, SCI, SKX, SRCL, SUSQ, SYK, TAL, TER, TEX, TQNT, TSCO, TWI, VAR, WCN, WDC, WLL, XLNX, XNPT, ZNGA Comment! [Earnings]
- Thursday, March 21, 9:27 AM The U.K.'s NICE health regulator has recommended that InterMune's (ITMN +10.6%) Esbriet therapy be used to treat mild-to-moderate idiopathic pulmonary fibrosis (IPF), of which there are 6,100-9,500 sufferers in England and Wales. IPF is a fatal lung disease. (PR) Comment! [Healthcare, On the Move]
-
Thursday, March 21, 9:10 AM
Premarket gainers: ITMN +12%. CBLI +9%. ACAD +7%. AFFY +6%.
Losers: CIMT -12%. SCHL -11%. BLDP -9%. ORCL -8%. GES -7%. Comment! [On the Move] -
Friday, March 1, 5:36 PM
After-hours top gainers, as of 5:15 p.m.: OUTD +13%. AVD +8%. ITMN +7%. JAKK +7%. GTI +6%.
After-hours top losers: CRIS -13%. BPZ -10%. AFCE -8%. CRM -7%. MKTG -7%. 4 Comments [On the Move] - Thursday, February 21, 4:11 PM InterMune (ITMN): Q4 EPS of -$0.90 misses by $0.04. Revenue of $8.2M misses by $0.11M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 21, 12:10 AM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD Comment! [Earnings]
- Wednesday, February 20, 5:35 PM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD 2 Comments [Earnings]
- Tuesday, January 15, 10:43 AM InterMune (ITMN -4.7%) slips after the company announces an offering of 12.5M shares as well as $85M aggregate principal amount of notes due in 2017. ITMN's float currently stands at around 66M shares. Comment! [Healthcare, On the Move]
-
Monday, January 14, 5:38 PM
After-hours top gainers, as of 5:15 p.m.: HWD +3%. BGC +3%. GTAT +3%. ESI +2%. MHO +2%.
After-hours top losers: LULU -7%. ITMN -5%. GMAN -4%. VNM -3%. UA -2%. Comment! [On the Move] - Friday, January 4, 11:07 AM InterMune (ITMN -1.2%) slips a bit this morning after saying late yesterday that 2013 revenue from sales of Esbriet will depend largely on the timing of its launch efforts in several European countries. The drug is designed for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease and is the only approved treatment worldwide. Comment! [Healthcare, Earnings, On the Move]
-
Thursday, January 3, 5:42 PM
After-hours top gainers, as of 5:15 p.m.: NAVB +5%. ROVI +5%. SHLM +5%. UVXY +2%. SNTS +2%.
After-hours top losers: ARAY -20%. VTNC -7%. SUSP -6%. ITMN -6%. FUN -5%. Comment! [On the Move] - Wednesday, December 26, 2012, 12:43 PM Three members of an independent FDA advisory panel say they received advanced information ahead of U.S. regulators in May 2010 regarding the rejection of a drug from InterMune (ITMN -2.5%), which is now at the heart of a trading investigation of SAC Capital. ITMN’s shares fell 5.4% the day before the company announced the rejection. However, others at the FDA were also aware of the rejection too, and there’s no evidence the 11 panelists did anything wrong. Comment! [Healthcare, On the Move]
- Friday, November 23, 2012, 12:42 PM Shares of InterMune (ITMN +7.8%) moves higher today on no significant news to speak of. One positive catalyst could be from an article posted in Seeking Alpha late Wednesday rating the stock a Buy. The gist of the article is that, despite the risk of company being dependent on a single product - Esbriet - for growth, the company has thrown all its marketing resources behind its launch and expects it to yield a high payout for the effort. Comment! [Healthcare, On the Move]
- Thursday, November 8, 2012, 11:58 AM Shares of Intermune (ITMN +16.3%) are higher today after handily beating Q3 estimates late yesterday. Net losses narrowed to $45.4M, or $0.70 per share, compared with a net loss of $38.2M, or $0.63 per share in the prior-year period. Sales of its lung-disease drug Esbriet have been strong, and the company says it expects FY12 sales to come in at or slightly above the high end of its estimated range. Canaccord ups the shares to Buy on the momentum. Comment! [Healthcare, On the Move, Earnings]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.